B
ALNY icon

BP’s Alnylam Pharmaceuticals ALNY Stock Holding History

BP’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-2,921
Closed -$495K – 31
2021
Q2 		$495K Sell
2,921
-1,178
-29% -$173K 0.02% 410
2021
Q1 		$579K Sell
4,099
-1,390
-25% -$209K 0.02% 437
2020
Q4 		$713K Sell
5,489
-4,711
-46% -$629K 0.02% 417
2020
Q3 		$1.48M Sell
10,200
-800
-7% -$114K 0.04% 351
2020
Q2 		$1.63M Hold
11,000
– – 0.06% 323
2020
Q1 		$1.2M Hold
11,000
– – 0.05% 345
2019
Q4 		$1.27M Buy
+11,000
New +$1.1M 0.04% 393
2018
Q3 		– Sell
-12,000
Closed -$1.18M – 474
2018
Q2 		$1.18M Buy
+12,000
New +$1.19M 0.04% 435

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

BP's ALNY Position: Q3 2021 in Review

BP sold out of Alnylam Pharmaceuticals (ALNY) in Q3 2021, closing a stake of 2,921 shares — an estimated $495K sold.

BP first reported a position in ALNY in Q2 2018 and held it in 8 quarters. The position peaked at $1.63M in Q2 2020. 405 funds tracked by Wall St. Rank hold ALNY as of Q3 2021.

  • BP reported no remaining Alnylam Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • BP sold 2,921 Alnylam Pharmaceuticals shares in Q3 2021, an estimated $495K.
  • BP first reported a position in Alnylam Pharmaceuticals in Q2 2018 and held it in 8 quarters.
  • BP's Alnylam Pharmaceuticals position peaked at $1.63M in Q2 2020.
  • 405 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q3 2021.

Based on BP's 13F filing for Q3 2021, filed 10 Nov 2021.